Observation study of Trastuzumab for HER2 positive advanced or recurrent gastric cancer

Observation study of Trastuzumab for HER2 positive advanced or recurrent gastric cancer - Observation study of Trastuzumab for HER2 positive advanced or recurrent gastric cancer(KSCC1105)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007246

Enrollment

Registered

2012-02-08

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Confirmed HER2 positive Treatment-Initiated after 10 March, 2011

Exclusion criteria

Exclusion criteria: Other than inclusion criteria

Design outcomes

Primary

Measure	Time frame
Safety (rate and grade of adverse event) Rate and grade of Infusion reaction and treatment Rate and grade of cardiac events, and correlation with treatment and outcome Treatment line Treatment regimen Response Rate Progression Free Survival Time to Failure of Strategy Time to Treatment Failure Overall Survival	—

Countries

Japan

Contacts

Public ContactKSCC secretariat

Clinical Research Support Center Kyushu KSCC secretariat

kscc2@cres-kyushu.or.jp092-631-2920

Outcome results